ZCCN INFO
832171
WUXI JINGHAI
836547
KLT
831689
TIRAIN
430564
ZHONGKE MEILING
835892
CN Stock MarketDetailed Quotes
002793 Luoxin Pharmaceuticals Group Stock
- 3.90
- +0.02+0.52%
Market Closed Mar 14 15:00 CST
4.24BMarket Cap-6.08P/E (TTM)
4.00High3.86Low208.46KlotVolume3.89Open3.88Pre Close81.73MTurnover1.92%Turnover RatioLossP/E (Static)1.09BShares5.3352wk High2.02P/B4.24BFloat Cap3.2252wk Low4.27Limit Up1.09BShs Float27.94Historical High3.49Limit Down3.61%Amplitude3.22Historical Low--Dividend TTM3.92Avg Price107.14KlotAsk--Div YieldTTM100Lot Size96.90KlotBid
Luoxin Pharmaceuticals Group Stock News
Luoxin Pharmaceutical: Announcement on obtaining a drug registration certificate for the atomized inhalation solution of levosalbutamol hydrochloride
Luoxin Pharmaceutical: Announcement on approval of new indications for injectable LX22001 to conduct clinical trials
Luoxin Pharmaceutical: Announcement on the cancellation of the controlling shareholder\'s share pledge
Luoxin Pharmaceutical: Legal Opinion of the Shanghai Branch of Beijing King & Wood Mallesons on the 2025 Second Extraordinary General Meeting of Shareholders of Luoxin Pharmaceutical Group Co., Ltd.
Luoxin Pharmaceutical: Announcement of Resolutions of the 2025 Second Extraordinary General Meeting of Shareholders
Luoxin Pharmaceutical: Progress Announcement on Providing Guarantees for Holding Subsidiaries
Luoxin Pharmaceutical: Announcement of Resolutions of the 20th Meeting of the Fifth Board of Supervisors
Luoxin Pharmaceutical: Comparison Table of Amendments to the Company\'s Articles of Association
Luoxin Pharmaceutical: Articles of Association (February 2025)
Luo Xin Pharmaceutical: Supervisory Board Rules of Procedure (February 2025)
Luoxin Pharmaceutical: Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2025
Luoxin Pharmaceutical: Announcement of Resolutions of the 23rd Meeting of the Fifth Board of Directors
Luo Xin Pharmaceutical: Announcement on the Resignation of Employee Representative Supervisor
Luoxin Pharmaceutical: Legal Opinion of the Shanghai Branch of Beijing King & Wood Mallesons on the 2025 First Extraordinary General Meeting of Shareholders of Luoxin Pharmaceutical Group Co., Ltd.
Luoxin Pharmaceutical: Announcement of Resolutions of the 2025 First Extraordinary General Meeting of Shareholders
Luoxin Pharmaceutical: Progress Announcement on Providing Guarantees for Holding Subsidiaries
Luoxin Pharmaceutical: 2024 Annual Results Forecast
Luoxin Pharmaceutical: Announcement on the controlling shareholder\'s share pledge
Luoxin Pharmaceutical: Notice on Convening the First Extraordinary General Meeting of Shareholders in 2025
Luo Xin Pharmaceutical: Announcement of Resolutions of the 19th Meeting of the Fifth Board of Supervisors
